CADL Stock Overview
A clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Candel Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.45 |
| 52 Week High | US$14.60 |
| 52 Week Low | US$3.79 |
| Beta | -0.91 |
| 1 Month Change | 11.00% |
| 3 Month Change | -39.28% |
| 1 Year Change | -38.76% |
| 3 Year Change | 44.56% |
| 5 Year Change | n/a |
| Change since IPO | -22.14% |
Recent News & Updates
Recent updates
Candel Therapeutics: CAN-2409's Promising Progress Deserves An Upgrade
May 27Candel Therapeutics: Entering Its Pivotal Year
Feb 20Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight
Dec 11Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway
Jul 01Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer
Apr 15Candel gets European orphan drug designation for brain, spinal cord tumor treatment
Sep 15Candel Therapeutics appoints CFO, chief medical officer
Sep 07Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies
Oct 21Shareholder Returns
| CADL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.4% | 2.6% | 1.2% |
| 1Y | -38.8% | -9.1% | 12.5% |
Return vs Industry: CADL underperformed the US Biotechs industry which returned -9.1% over the past year.
Return vs Market: CADL underperformed the US Market which returned 12.5% over the past year.
Price Volatility
| CADL volatility | |
|---|---|
| CADL Average Weekly Movement | 12.6% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: CADL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CADL's weekly volatility has decreased from 18% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 38 | Paul-Peter Tak | www.candeltx.com |
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma.
Candel Therapeutics, Inc. Fundamentals Summary
| CADL fundamental statistics | |
|---|---|
| Market cap | US$293.10m |
| Earnings (TTM) | -US$39.58m |
| Revenue (TTM) | n/a |
Is CADL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CADL income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$18.13m |
| Gross Profit | -US$18.13m |
| Other Expenses | US$21.44m |
| Earnings | -US$39.58m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.79 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 13.5% |
How did CADL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/30 00:49 |
| End of Day Share Price | 2025/05/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Candel Therapeutics, Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Evan Seigerman | BMO Capital Markets Equity Research |
| Alec Stranahan | BofA Global Research |
| John Newman | Canaccord Genuity |